内容紹介
Comparative Evaluation of 2 Antiemesis Tools for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Summary
Although recent advances in chemotherapy have led to improved quality of life(QOL)and prolonged survival in patients with advanced cancer, treatment is often discontinued because of adverse events associated with chemotherapy, regardless of its efficacy. Nevertheless, chemotherapy has been validated in the United States and United Kingdom and is used worldwide. In Japan, few reports have been published regarding the use of assessment tools including the Multinational Association of Supportive Care in Cancer(MASCC)Antiemesis Tool(MAT)for the evaluation of chemotherapy-induced nausea and vomiting(CINV). We prospectively investigated the utility of the MAT and digestive symptom diary(DSD). In total, 68 patients who underwent highly and moderately emetogenic chemotherapy were included in the efficacy analyses. The improvement in the control of CINV during the delayed phase was significantly different between the DSD and MAT groups(p=0.0148). The results obtained using the MAT warrant further validation. Meanwhile, the DSD may be used as an information tool by medical staff and patients.
要旨
化学療法時の悪心・嘔吐は,QOLを低下させることはもとよりコンプライアンス低下を招き,治療に悪影響を与える可能性がある。一方,化学療法時の悪心・嘔吐の評価方法に関しては,一定のコンセンサスはなく,各施設で独自の評価方法を用いているのが現状である。今回,当院にて高度または中等度催吐性化学療法を施行された68症例を対象に日本語版MATと消化器症状日誌の妥当性を検討した結果,日本語版MATと消化器症状日誌の間に遅発性のcomplete control(CC)率の検出力に差を認めた(p=0.0148)。今回の結果から,日本語版MATはさらなるバリデーションが必要と考えられ,当院では医師,薬剤師,看護師と患者の情報の架け橋として消化器症状日誌を活用する予定である。
目次
Summary
Although recent advances in chemotherapy have led to improved quality of life(QOL)and prolonged survival in patients with advanced cancer, treatment is often discontinued because of adverse events associated with chemotherapy, regardless of its efficacy. Nevertheless, chemotherapy has been validated in the United States and United Kingdom and is used worldwide. In Japan, few reports have been published regarding the use of assessment tools including the Multinational Association of Supportive Care in Cancer(MASCC)Antiemesis Tool(MAT)for the evaluation of chemotherapy-induced nausea and vomiting(CINV). We prospectively investigated the utility of the MAT and digestive symptom diary(DSD). In total, 68 patients who underwent highly and moderately emetogenic chemotherapy were included in the efficacy analyses. The improvement in the control of CINV during the delayed phase was significantly different between the DSD and MAT groups(p=0.0148). The results obtained using the MAT warrant further validation. Meanwhile, the DSD may be used as an information tool by medical staff and patients.
要旨
化学療法時の悪心・嘔吐は,QOLを低下させることはもとよりコンプライアンス低下を招き,治療に悪影響を与える可能性がある。一方,化学療法時の悪心・嘔吐の評価方法に関しては,一定のコンセンサスはなく,各施設で独自の評価方法を用いているのが現状である。今回,当院にて高度または中等度催吐性化学療法を施行された68症例を対象に日本語版MATと消化器症状日誌の妥当性を検討した結果,日本語版MATと消化器症状日誌の間に遅発性のcomplete control(CC)率の検出力に差を認めた(p=0.0148)。今回の結果から,日本語版MATはさらなるバリデーションが必要と考えられ,当院では医師,薬剤師,看護師と患者の情報の架け橋として消化器症状日誌を活用する予定である。